GlassScriptPhysician profile
Jason Litsky
NPI 1114169539
$6,621.08
in general payments reported to CMS, 2019-2025
25 companies · $1,094 in 2025
The $1,094 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $807 · 2021: $1,492 · 2022: $781 · 2023: $650 · 2024: $1,137 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,880.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,234.95 | 2019-2025 | Ensite, Supera |
| Boston Scientific Corporation | $1,453.92 | 2019-2025 | Avvigo Guidance System, Eluvia, General - Tachy |
| Abiomed | $432.42 | 2023-2025 | Impella |
| Shockwave Medical, INC | $408.41 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $330.22 | 2021-2025 | Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $314.46 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $291.38 | 2021-2025 | |
| Cardiovascular Systems INC. | $211.79 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.07 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $143.11 | 2020-2025 | Andexxa, Wainua |
| Pfizer INC. | $124.01 | 2019-2025 | |
| Imperative Care, INC | $119.39 | 2025 | Symphony Catheter |
| Impulse Dynamics (USA) INC. | $71.09 | 2022 | |
| Amgen INC. | $69.85 | 2024-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $34.45 | 2025 | Onpattro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.87 | 2021-2023 | Ozempic |
| Chiesi USA, INC. | $30.83 | 2025 | Kengreal |
| Sanofi-Aventis U.S. LLC | $29.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.67 | 2024 | Eliquis |
| Ge Healthcare | $17.11 | 2024 | |
| Esperion Therapeutics, INC. | $15.74 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.76 | 2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $13.57 | 2024 | Assure Wcd |
| Portola Pharmaceuticals, LLC | $12.79 | 2019 | |
| Cardinal Health 200 LLC | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Litsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.